Ligosan

Doxycycline hyclate, the active ingredient in Ligosan, is a tetracycline antibiotic presented as a periodontal formulation for local use. It is employed to treat bacterial infections of the gums and supporting structures, particularly in patients with chronic periodontal disease. The product conforms to European Union marketing standards and is manufactured under strict Good Manufacturing Practice guidelines.

GNH USA supplies Ligosan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance, and reliable global logistics.

Ligosan (doxycycline hyclate) is indicated for bacterial infections affecting the periodontal tissues and related oral conditions.

- Periodontal disease: reduces bacterial load and inflammation, helping to stabilize the periodontal attachment. - Acute necrotizing ulcerative gingivitis: controls rapidly progressing infection and alleviates pain and tissue necrosis. - Chronic periodontitis: limits disease progression by inhibiting collagenase activity of pathogenic bacteria. - Post‑extraction socket infection: prevents bacterial colonisation and promotes healing after dental surgery.

Adverse reactions may occur with doxycycline therapy and should be monitored.

Common Side Effects: - Nausea - Vomiting - Diarrhoea - Photosensitivity - Abdominal pain - Altered taste perception

Serious or Rare Side Effects: - Anaphylactic reaction or severe hypersensitivity - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Hepatic toxicity (elevated transaminases, hepatitis) - Intracranial hypertension (pseudotumor cerebri) - Severe photosensitivity leading to burns - Clostridioides difficile‑associated colitis

When prescribing Ligosan, consider the following precautions.

- Pregnancy: Category D – avoid unless the therapeutic benefit outweighs potential fetal risk. - Breastfeeding: Doxycycline may be excreted in milk; assess risk versus benefit. - Renal impairment: dose adjustment may be required in patients with reduced clearance. - Hepatic disease: use with caution; monitor liver function tests. - Photosensitivity: advise patients to limit exposure to strong sunlight and use protective clothing. - Store at below 25°C: keep in the original packaging, protect from moisture and direct light.

Doxycycline hyclate can interact with several medicines; monitoring is essential.

Major Interactions (Avoid): - Antacids containing aluminium or magnesium: markedly reduce doxycycline absorption. - Oral iron supplements: chelate the drug and diminish its bioavailability. - Warfarin: may potentiate anticoagulant effect and increase bleeding risk. - Retinoids (e.g., isotretinoin): increase the likelihood of intracranial hypertension. - Live vaccines: may attenuate vaccine efficacy.

Moderate Interactions (Monitor Closely): - Barbiturates: induce hepatic enzymes, lowering doxycycline plasma levels. - Carbamazepine: similar enzyme‑inducing effect, potentially reducing efficacy. - Oral contraceptives: may decrease contraceptive reliability; advise additional protection. - Theophylline: increased clearance may reduce therapeutic effect. - Cyclosporine: doxycycline can raise cyclosporine serum concentrations.